<DOC>
	<DOCNO>NCT01326871</DOCNO>
	<brief_summary>This Phase Ib/II , open-label , multi-center , competitive enrollment dose-escalation study ALT-801 biochemotherapy regimen either contain cisplatin gemcitabine contain gemcitabine alone patient muscle invasive metastatic urothelial cancer bladder , renal pelvis , ureter urethra . The purpose study evaluate safety , determine maximum tolerate dose ( MTD ) recommend dose ( RD ) , assess anti-tumor response ALT-801 combination cisplatin gemcitabine ALT-801 combination gemcitabine alone . The pharmacokinetic profile ALT-801 combination cisplatin gemcitabine also assess . The study include dose escalation phase ( Phase Ib ) dose expansion phase ( Phase II ) . Phase II two treatment group , Expansion Group 1 Expansion Group 2 . Expansion Group 2 platinum-refractory patient , consist two treatment arm base patient 's renal function . Patients enroll Expansion Group 2 stage 1 Group 1 expansion complete .</brief_summary>
	<brief_title>A Study ALT-801 Combination With Cisplatin Gemcitabine Muscle Invasive Metastatic Urothelial Cancer</brief_title>
	<detailed_description>Bladder cancer fourth common malignancy men ninth common woman US , estimate 68,810 new case 14,070 death year 2008 . Approximately 90 % 95 % newly diagnose patient transitional cell carcinoma ( TCC ) . Approximately 20 % 25 % contain advance ( muscle invasive metastatic ) disease . Muscle invasive bladder cancer life threaten . Clinical trial demonstrate TCC chemotherapy-sensitive malignancy . Most current cancer treatment strategy involve use chemotherapeutic biological drug low therapeutic ratio . The limitation consequence effect therapeutic drug normal tissue . One approach control systemic exposure effect target drug site tumor . For example , antibody develop use tumor target agent success clinic . However , despite promise antibody-based immunotherapy , limitation class reagent . Even , immunotherapy remain promising approach treat cancer . One strategy receive attention treatment cytokine IL-2 enhance anti-tumor immunity . IL-2 stimulatory effect number immune cell type include T B cell , monocyte , macrophage , lymphokine-activated killer cell ( LAK ) natural killer ( NK ) cell . Based ability IL-2 provide durable curative anti-tumor response , systemic administration IL-2 approve treat patient metastatic melanoma renal carcinoma . Unfortunately , considerable toxicity associate treatment make difficult achieve effective dose site tumor limit population treat . Thus , critical need innovative strategy enhance effect IL-2 , reduce toxicity without compromise clinical benefit , treat diagnosis . The study drug , ALT-801 , biologic compound interleukin-2 ( IL-2 ) genetically fuse humanize soluble T-cell receptor direct p53-derived peptide express tumor cell . The p53 protein one important factor protect develop cancer also one frequently mutate gene many cancer , include muscle-invasive bladder cancer . For give cancer type , p53 dysfunction generally correlate poor prognosis versus site-of-origin . In tumor , p53 mutation over-expression also associate resistance chemotherapy . This study evaluate whether direct IL-2 activity use ALT-801 patient 's tumor sit over-express p53 result clinical benefit</detailed_description>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>ENTRY CRITERIA : DISEASE CHARATERISTICS : Muscle invasive metastatic urothelial cancer bladder , ureter , renal pelvis , urethra Histologically cytologically confirm clinical plan would potentially include cisplatin* plus gemcitabine systemic therapy disease refractory firstline platinumbased therapy ( define protocol ) . * Does apply patient screen Phase II expansion Surgically incurable PRIOR/CONCURRENT THERAPY : No concurrent radiotherapy , chemotherapy , immunotherapy Must recover side effect prior treatment If prior Proleukin® treatment , must clinical benefit No use investigational agent within 30 day start concurrently PATIENT CHARACTERISTICS : Age ≥ 18 year Performance Status ECOG 0 1 Bone Marrow Reserve Absolute neutrophil count ( AGC/ANC ) ≥ 1,500/uL Platelets ≥ 100,000/uL Hemoglobin ≥ 10g/dL Renal Function Glomerular Filtration Rate ( GFR ) : ≥ 50mL/min/1.73m^2 cisplatincontaining regimen ≥ 40mL/min/1.73m^2 noncisplatincontaining regimen Hepatic Function Total bilirubin ≤ 1.5 X ULN AST , ALT , ALP ≤ 2.5 X ULN , ≤ 5.0 X ULN ( liver metastasis exists ) PT INR ≤ 1.5 X ULN Cardiovascular No congestive heart failure &lt; 6 month No unstable angina pectoris &lt; 6 month No myocardial infarction &lt; 6 month No history ventricular arrhythmia No NYHA Class &gt; II CHF Normal cardiac stress test require subject ≥ 50 year old , history EKG abnormality , symptom cardiac ischemia arrhythmia No uncontrolled hypertension Pulmonary Not receive chronic medication asthma Normal clinical assessment pulmonary function Hematologic No evidence bleed diathesis coagulopathy Other Negative serum pregnancy test female childbearing potential No woman pregnant nursing Subjects , female male , reproductive potential must agree use effective contraceptive measure duration study No know autoimmune disease correct hypothyroidism No know prior organ allograft allogeneic transplantation Not HIV positive No active systemic infection require parenteral antibiotic therapy No ongoing systemic steroid therapy require No history evidence CNS disease ( Controlled brain metastasis treat radiation therapy surgery disease clinically stable period least 3 month screen allow ) No psychiatric illness/social situation No illness opinion investigator would exclude subject participate study Must provide inform consent HIPAA authorization agree comply protocolspecified procedure followup evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>immunochemotherapy</keyword>
	<keyword>combinational therapy</keyword>
	<keyword>target</keyword>
	<keyword>metastatic</keyword>
	<keyword>muscle invasive</keyword>
	<keyword>interleukin-2</keyword>
	<keyword>cisplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>antitumor</keyword>
	<keyword>TCR</keyword>
	<keyword>T-cell receptor</keyword>
	<keyword>p53</keyword>
	<keyword>p53 gene</keyword>
	<keyword>p53 tumor supressor protein</keyword>
	<keyword>urothelial cancer</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>renal pelvis cancer</keyword>
	<keyword>ureter cancer</keyword>
	<keyword>urethra cancer</keyword>
	<keyword>HLA-A2 positive</keyword>
	<keyword>HLA-A*0201/p53 aa264-272</keyword>
	<keyword>HLA complex</keyword>
	<keyword>Muscle Invasive Metastatic</keyword>
</DOC>